{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T13:41:29Z","timestamp":1793367689877,"version":"4.5.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371057"],"award-info":[{"award-number":["82371057"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Retinal degenerative diseases, including glaucoma, age-related macular degeneration, diabetic retinopathy, and a broad range of inherited retinal diseases, are leading causes of irreversible vision loss and blindness. Gene therapy is a promising and fast-growing strategy to treat both monogenic and multifactorial retinal disorders. Vectors for gene delivery are crucial for efficient and specific transfer of therapeutic gene(s) into target cells. AAV vectors are ideal for retinal gene therapy due to their inherent advantages in safety, gene expression stability, and amenability for directional engineering. The eye is a highly compartmentalized organ composed of multiple disease-related cell types. To determine a suitable AAV vector for a specific cell type, the route of administration and choice of AAV variant must be considered together. Here, we provide a brief overview of AAV vectors for gene transfer into important ocular cell types, including retinal pigment epithelium cells, photoreceptors, retinal ganglion cells, M\u00fcller glial cells, ciliary epithelial cells, trabecular meshwork cells, vascular endothelial cells, and pericytes, via distinct injection methods. By listing suitable AAV vectors in basic research and (pre)clinical studies, we aim to highlight the progress and unmet needs of AAV vectors in retinal gene therapy.<\/jats:p>","DOI":"10.3389\/fmed.2023.1310050","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T18:37:39Z","timestamp":1701455859000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Adeno-associated virus vectors for retinal gene therapy in basic research and clinical studies"],"prefix":"10.3389","volume":"10","author":[{"given":"Xue","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1001\/archopht.1974.03900060147013","article-title":"Physiological chemistry of the eye","volume":"91","author":"Barber","year":"1974","journal-title":"Arch Ophthalmol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0014-4835(77)80024-9","article-title":"The physiology and pathophysiology of intraocular fluids","volume":"25","author":"Bito","year":"1977","journal-title":"Exp Eye Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preteyeres.2014.06.003","article-title":"Functional architecture of the retina: development and disease","volume":"42","author":"Hoon","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1021\/acs.jmedchem.5b00828","article-title":"Discovery of molecular therapeutics for glaucoma: challenges, successes, and promising directions","volume":"59","author":"Donegan","year":"2016","journal-title":"J Med Chem"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1242\/jcs.175687","article-title":"Photoreceptors at a glance","volume":"128","author":"Molday","year":"2015","journal-title":"J Cell Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"13467","DOI":"10.3390\/ijms232113467","article-title":"Inherited retinal diseases","volume":"23","author":"Ben-Yosef","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2021.04.027","article-title":"Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis","volume":"128","author":"Teo","year":"2021","journal-title":"Ophthalmology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1073\/pnas.1913179117","article-title":"Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases","volume":"117","author":"Hanany","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"101195","DOI":"10.1016\/j.mam.2023.101195","article-title":"The molecular aspect of anti-glaucomatous eye drops\u2014are we harming our patients?","volume":"93","author":"Hedengran","year":"2023","journal-title":"Mol Asp Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1185\/030079908X291976","article-title":"Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice","volume":"24","author":"Vorwerk","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ophtha.2013.09.003","article-title":"Long-term trends in glaucoma-related blindness in Olmsted County, Minnesota","volume":"121","author":"Malihi","year":"2014","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1136\/bjo.2009.174912","article-title":"Gene therapy for ocular diseases","volume":"95","author":"Liu","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2147\/OPTH.S364200","article-title":"Ocular gene therapy: a literature review with special focus on immune and inflammatory responses","volume":"16","author":"Ghoraba","year":"2022","journal-title":"Clin Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/nbt0118-6a","article-title":"FDA approves hereditary blindness gene therapy","volume":"36","year":"2018","journal-title":"Nat Biotechnol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4274\/tjo.galenos.2021.74944","article-title":"Frequency of RPE65 gene mutation in patients with hereditary retinal dystrophy","volume":"52","author":"Kahraman","year":"2022","journal-title":"Turk J Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e29533","DOI":"10.7759\/cureus.29533","article-title":"Ocular gene therapy: a literature review with focus on current clinical trials","volume":"14","author":"Wasnik","year":"2022","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/TACG.S383453","article-title":"Adeno-associated virus (AAV)\u2014based gene therapies for retinal diseases: where are we?","volume":"16","author":"Ail","year":"2023","journal-title":"Appl Clin Genet"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"113324","DOI":"10.1016\/j.biopha.2022.113324","article-title":"Gene therapy clinical trials, where do we go? An overview","volume":"153","author":"Arabi","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu Rev Virol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1089\/hum.2020.138","article-title":"Adeno-associated virus-based gene therapy for lifelong correction of genetic disease","volume":"31","author":"Brommel","year":"2020","journal-title":"Hum Gene Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1093\/hmg\/5.5.591","article-title":"Gene transfer into the mouse retina mediated by an adeno-associated viral vector","volume":"5","author":"Ali","year":"1996","journal-title":"Hum Mol Genet"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.preteyeres.2014.08.001","article-title":"Vector platforms for gene therapy of inherited retinopathies","volume":"43","author":"Trapani","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.3390\/pharmaceutics14091931","article-title":"Ocular drug delivery: advancements and innovations","volume":"14","author":"Tian","year":"2022","journal-title":"Pharmaceutics"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1152\/physrev.00021.2004","article-title":"The retinal pigment epithelium in visual function","volume":"85","author":"Strauss","year":"2005","journal-title":"Physiol Rev"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/jgm.1126","article-title":"Novel AAV serotypes for improved ocular gene transfer","volume":"10","author":"Lebherz","year":"2008","journal-title":"J Gene Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"7651","DOI":"10.1128\/JVI.76.15.7651-7660.2002","article-title":"Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size","volume":"76","author":"Yang","year":"2002","journal-title":"J Virol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S1525-0016(03)00098-4","article-title":"Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery","volume":"7","author":"Weber","year":"2003","journal-title":"Mol Ther"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/hmg\/10.26.3075","article-title":"Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model","volume":"10","author":"Auricchio","year":"2001","journal-title":"Hum Mol Genet"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In vivo-directed evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.1101\/2021.06.24.449775","article-title":"Directed evolution of AAV targeting primate retina by intravitreal injection identifies R100, a variant demonstrating robust gene delivery and therapeutic efficacy in non-human primates","author":"Kotterman","year":""},{"key":"ref36","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1172\/JCI129085","article-title":"AAV8-vectored suprachoroidal gene transfer produces widespread ocular transgene expression","volume":"129","author":"Ding","year":"2019","journal-title":"J Clin Invest"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/jop.2019.0126","article-title":"Suprachoroidal delivery of viral and nonviral gene therapy for retinal diseases","volume":"36","author":"Kansara","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.omtm.2020.01.002","article-title":"Suprachoroidal and subretinal injections of AAV using transscleral microneedles for retinal gene delivery in nonhuman primates","volume":"16","author":"Yiu","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/mt.2010.234","article-title":"Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina","volume":"19","author":"Petrs-Silva","year":"2011","journal-title":"Mol Ther"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"11372","DOI":"10.1128\/JVI.01327-07","article-title":"Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors","volume":"81","author":"Allocca","year":"2007","journal-title":"J Virol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e6317","DOI":"10.7717\/peerj.6317","article-title":"Evaluation of AAV-DJ vector for retinal gene therapy","volume":"7","author":"Katada","year":"2019","journal-title":"PeerJ"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"88ra54","DOI":"10.1126\/scitranslmed.3002103","article-title":"Dosage thresholds for AAV2 and AAV8 photoreceptor gene therapy in monkey","volume":"3","author":"Vandenberghe","year":"2011","journal-title":"Sci Transl Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"e13392","DOI":"10.15252\/emmm.202013392","article-title":"Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders","volume":"13","author":"Pavlou","year":"2021","journal-title":"EMBO Mol Med"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/02713683.2019.1565890","article-title":"Morphology and composition of the inner limiting membrane: species-specific variations and relevance toward drug delivery research","volume":"44","author":"Peynshaert","year":"2019","journal-title":"Curr Eye Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1350-9462(02)00012-5","article-title":"Retinal ganglion cell disorders: types and treatments","volume":"21","author":"Levin","year":"2002","journal-title":"Prog Retin Eye Res"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1126\/science.1161566","article-title":"Promoting axon regeneration in the adult CNS by modulation of the PTEN\/mTOR pathway","volume":"322","author":"Park","year":"2008","journal-title":"Science"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"100932","DOI":"10.1016\/j.xpro.2021.100932","article-title":"Protocol for evaluating the role of a gene in protecting mouse retinal ganglion cells","volume":"2","author":"Guo","year":"2021","journal-title":"STAR Protoc"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1167\/iovs.10-6250","article-title":"Intravitreal injection of AAV2 transduces macaque inner retina","volume":"52","author":"Yin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/IIO.0000000000000364","article-title":"Gene therapies for the treatment of Leber hereditary optic neuropathy","volume":"61","author":"Sahel","year":"2021","journal-title":"Int Ophthalmol Clin"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/978-1-4939-9139-6_14","article-title":"SubILM injection of AAV for gene delivery to the retina","volume":"1950","author":"Gamlin","year":"2019","journal-title":"Methods Mol Biol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1089\/hum.2016.085","article-title":"Highly efficient delivery of adeno-associated viral vectors to the primate retina","volume":"27","author":"Boye","year":"2016","journal-title":"Hum Gene Ther"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"14009","DOI":"10.1038\/mtm.2014.9","article-title":"Specific tools for targeting and expression in M\u00fcller glial cells","volume":"1","author":"Pellissier","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.preteyeres.2006.05.003","article-title":"M\u00fcller cells in the healthy and diseased retina","volume":"25","author":"Bringmann","year":"2006","journal-title":"Prog Retin Eye Res"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/ng1097-198","article-title":"Mutation of the gene encoding cellular retinaldehyde-binding protein in autosomal recessive retinitis pigmentosa","volume":"17","author":"Maw","year":"1997","journal-title":"Nat Genet"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/13848","article-title":"Mutations in a human homologue of Drosophila crumbs cause retinitis pigmentosa (RP12)","volume":"23","author":"den Hollander","year":"1999","journal-title":"Nat Genet"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.drudis.2019.01.023","article-title":"M\u00fcller cells as a target for retinal therapy","volume":"24","author":"Devoldere","year":"2019","journal-title":"Drug Discov Today"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.omtm.2023.05.016","article-title":"In-depth comparison of Anc80L65 and AAV9 retinal targeting and characterization of cross-reactivity to multiple AAV serotypes in humans","volume":"30","author":"Schwartz","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"e7467","DOI":"10.1371\/journal.pone.0007467","article-title":"A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat M\u00fcller cells","volume":"4","author":"Klimczak","year":"2009","journal-title":"PLoS One"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1038\/mt.2009.184","article-title":"Molecular evolution of adeno-associated virus for enhanced glial gene delivery","volume":"17","author":"Koerber","year":"2009","journal-title":"Mol Ther"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1874364101004010052","article-title":"Aqueous humor dynamics: a review","volume":"4","author":"Goel","year":"2010","journal-title":"Open Ophthalmol J"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/ICU.0b013e32834371d2","article-title":"Gene therapy for glaucoma","volume":"22","author":"Demetriades","year":"2011","journal-title":"Curr Opin Ophthalmol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.survophthal.2009.04.003","article-title":"Gene therapy targeting glaucoma: where are we?","volume":"54","author":"Liu","year":"2009","journal-title":"Surv Ophthalmol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"114781","DOI":"10.1016\/j.addr.2023.114781","article-title":"Gene therapy strategies for glaucoma from IOP reduction to retinal neuroprotection: Progress towards non-viral systems","volume":"196","author":"Hakim","year":"2023","journal-title":"Adv Drug Deliv Rev"},{"key":"ref64","first-page":"2513","article-title":"Gene therapy for glaucoma: treating a multifaceted, chronic disease","volume":"43","author":"Borras","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e0128759","DOI":"10.1371\/journal.pone.0128759","article-title":"Capsid mutated adeno-associated virus delivered to the anterior chamber results in efficient transduction of trabecular meshwork in mouse and rat","volume":"10","author":"Bogner","year":"2015","journal-title":"PLoS One"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.omtm.2019.06.009","article-title":"Transduction pattern of AAVs in the trabecular meshwork and anterior-segment structures in a rat model of ocular hypertension","volume":"14","author":"Lee","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1167\/iovs.09-3847","article-title":"Self-complementary AAV virus (scAAV) safe and long-term gene transfer in the trabecular meshwork of living rats and monkeys","volume":"51","author":"Buie","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1167\/iovs.63.13.15","article-title":"Intracameral injection of AAV-DJ.COMP-ANG1 reduces the IOP of mice by reshaping the trabecular outflow pathway","volume":"63","author":"Qiao","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ymthe.2019.12.012","article-title":"Gene therapy for glaucoma by ciliary body aquaporin 1 disruption using CRISPR-Cas9","volume":"28","author":"Wu","year":"2020","journal-title":"Mol Ther"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.omtm.2019.11.017","article-title":"C3 transferase-expressing scAAV2 transduces ocular anterior segment tissues and lowers intraocular pressure in mouse and monkey","volume":"17","author":"Tan","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41434-019-0105-4","article-title":"Transduction optimization of AAV vectors for human gene therapy of glaucoma and their reversed cell entry characteristics","volume":"27","author":"Rodriguez-Estevez","year":"2020","journal-title":"Gene Ther"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1093\/hmg\/ddac043","article-title":"Choroidal endothelial and macrophage gene expression in atrophic and neovascular macular degeneration","volume":"31","author":"Voigt","year":"2022","journal-title":"Hum Mol Genet"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3389\/fphar.2019.01363","article-title":"Choroidal neovascularization: mechanisms of endothelial dysfunction","volume":"10","author":"Yeo","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.3390\/ijms19123846","article-title":"The different facades of retinal and choroidal endothelial cells in response to hypoxia","volume":"19","author":"Alizadeh","year":"2018","journal-title":"Int J Mol Sci"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.preteyeres.2012.08.004","article-title":"Role of the retinal vascular endothelial cell in ocular disease","volume":"32","author":"Bharadwaj","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030458","article-title":"Retinal vascular endothelial cell dysfunction and neuroretinal degeneration in diabetic patients","volume":"10","author":"Mrugacz","year":"2021","journal-title":"J Clin Med"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"609","DOI":"10.15252\/emmm.201506078","article-title":"A brain microvasculature endothelial cell-specific viral vector with the potential to treat neurovascular and neurological diseases","volume":"8","author":"Korbelin","year":"2016","journal-title":"EMBO Mol Med"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/cne.25277","article-title":"AAV-BR1 targets endothelial cells in the retina to reveal their morphological diversity and to deliver Cx43","volume":"530","author":"Ivanova","year":"2022","journal-title":"J Comp Neurol"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fncel.2016.00020","article-title":"Brain and retinal pericytes: origin, function and role","volume":"10","author":"Trost","year":"2016","journal-title":"Front Cell Neurosci"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.3390\/ijms20246351","article-title":"Pericytes in microvessels: from \u201cmural\u201d function to brain and retina regeneration","volume":"20","author":"Caporarello","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"dmm032060","DOI":"10.1242\/dmm.032060","article-title":"Choroidal pericytes promote subretinal fibrosis after experimental photocoagulation","volume":"11","author":"Luo","year":"2018","journal-title":"Dis Model Mech"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/hum.2022.211","article-title":"An engineered adeno-associated virus capsid mediates efficient transduction of pericytes and smooth muscle cells of the brain vasculature","volume":"34","author":"Ramirez","year":"2023","journal-title":"Hum Gene Ther"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1167\/tvst.11.8.28","article-title":"Identification of novel retinal pericyte-targeting rAAV vectors through directed evolution","volume":"11","author":"Patel","year":"2022","journal-title":"Transl Vis Sci Technol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1310050\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T18:37:55Z","timestamp":1701455875000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1310050\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":83,"alternative-id":["10.3389\/fmed.2023.1310050"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1310050","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"article-number":"1310050"}}